Tcelltech Inc. is advancing TX103, an anti-B7-H3 CAR-T cell therapy, through a Phase I trial aimed at treating recurrent or progressive Grade 4 glioma, including glioblastoma. The market for glioma therapies is significant, with a growing demand for innovative treatments due to the limited efficacy of current standard-of-care options. The competitive landscape includes other CAR-T therapies and immunotherapies targeting gliomas, but TX103's specific targeting of B7-H3 may offer a differentiated approach. Successful outcomes could position Tcelltech favorably for partnerships or acquisitions, particularly given the high unmet need in this patient population. Diligence should focus on the safety profile and potential for dose-limiting toxicities, as well as the robustness of the clinical data supporting efficacy.